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INTRODUCTION 
 
Chronic kidney disease (CKD) is one of the most 
common clinical problems among older people [1–3]. 
The CKD prevalence is reported to be as high as one-
third to one-half of the elderly population [1, 4, 5]. With 
the improvement of life expectancy, the number of 
elderly patients with CKD is expected to increase much 
faster than at present. The increased prevalence of 
traditional risk factors, such as diabetes and 
hypertension, in the elderly is presumed to be the main 
cause of the pervasiveness of CKD in this population  
[6]. Nonetheless, the factors associated with CKD 
development in the elderly are not yet fully understood. 
 
Sarcopenia is a syndrome characterized by involuntary 
generalized loss of skeletal muscle mass and strength 
[7]. Muscle mass and strength begin to decline as early 
as the third decade of life and progressively deteriorate 
with aging in a linear manner [8]. In a recent meta-
analysis, the prevalence of sarcopenia was estimated to 
be about 10% of the population aged > 60 years 
worldwide when sarcopenia is defined by low muscle 
mass alone [9]. When taking muscle strength into 
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Sarcopenia, which is characterized by muscle mass and physical performance, is closely associated with 
morbidities and mortality, especially among the elderly. However, the effect of physical performance on 
chronic kidney disease (CKD) development is not yet fully elucidated. A total of 30,871 adults aged 66 years 
with preserved renal function who underwent health screening examinations were evaluated. Physical 
performance was assessed using a 3-m timed up and go (TUG) test and the one-leg stand (OLS) test. The 
primary outcome was the development of CKD, defined as at least two consecutive measurements of estimated 
glomerular filtration rate < 60 mL/min/1.73 m2. The rates of mortality and incident CKD development were 
significantly elevated with increases in TUG test scores but not in OLS scores. In the Cox hazards model, the 
highest TUG test score tertile was associated with an increased risk for CKD development (hazard ratio, 1.23; 
95% confidence interval, 1.10-1.38) compared with the lowest tertile. No significant relationship was observed 
between OLS score and incident CKD risk. Poor physical performance, assessed using the TUG test, was related 
to an increased risk of CKD development. 
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consideration, up to 50% of muscle strength is reported 
to be lost by the eighth decade of life [10, 11]. 
Sarcopenia in the elderly is accompanied by loss of 
function, disability, and frailty [12–14]. However, 
previous studies have shown that the presence of 
sarcopenia also increases the risk of several chronic 
diseases such as insulin resistance and rheumatoid 
arthritis, as well as mortality risk [15–20]. 
 
Recently, in addition to muscle mass measurements, 
evaluation of muscle performance has been emphasized 
in detecting sarcopenia. The European Working Group 
on Sarcopenia in Older People (EWGSOP) recently 
recommended considering muscle performance in 
addition to muscle mass when defining sarcopenia [21]. 
Further, the Society of Sarcopenia, Cachexia, and 
Wasting Disorders published a definition that includes 
the measurement of walking speed [22]. Nonetheless, 
despite the prevalence of sarcopenia and CKD among 
the elderly, the relationship between physical 
performance and CKD development has not been 
widely evaluated. 
 
Therefore, in this study, the association of physical 
performance, measured using the 3-m timed up and go 
(TUG) test and one-leg stand (OLS) test, with the 
development of incident CKD was investigated. This 







The baseline characteristics of the subjects according to 
tertiles of TUG and OLS test scores are shown in Table 
1 and Supplementary Table 1, respectively. Among the 
30,871 subjects, 15,070 (48.8%) were men. The mean 
estimated glomerular filtration rate (eGFR) was 84.9 ± 
19.2 mL/min/1.73 m2. During the study period, more 
than 72.9% of subjects measured creatinine ≥4 times 
(Supplementary Figure 1). The median (interquartile 
range) TUG and OLS test scores were 9 (7-10) and 16 
(10-20) seconds, respectively. The subjects in the higher 
TUG tertile groups tended to be women, have higher 
BMI, and frequently have a history of smoking. In 
addition, the proportions of subjects with chronic 
diseases including diabetes mellitus, hypertension, and 
cardiovascular disease (CVD) were elevated in tertile 
groups with higher TUG test scores. The proportions of 
subjects with dementia and malignancy were 
comparable among the groups. When the subjects were 
categorized according to OLS test scores, those in the 
higher OLS test score groups tended to be men, have 
lower BMI, and less likely have a history of CVD. 
Since baseline eGFR was lower in the lower TUG 
groups than the groups with higher TUG, the correlation 
between baseline eGFR and physical performance tests 
were examined using Pearson correlation analysis. The 
TUG test scores were positively associated with 
baseline eGFR (r=0.0321, P<.001) while OLS test 
scores did not show a significant correlation 




During a median of 6.0 (5.3-7.3) years and 181,627 
person-years, there were 905 deaths of any cause and 
2142 incident CKD events. The causes of mortality are 
shown in Supplementary Table 2. No significant 
association was found between specific mortality cause 
and physical activity. The incidence rate of CKD per 
1000 person-years was 11.8 among the overall subjects. 
The corresponding rate of death was 5.0. The rates of 
CKD development and mortality were increased in the 
higher TUG tertile groups (P=.001 and P=.01, 
respectively) (Table 2). When the subjects were divided 
into tertiles of OLS test scores, the rate of incident CKD 
was comparable among the OLS tertile groups. 
Although the mortality rates significantly differed 
among the OLS tertile groups, no clear trend of change 
was observed (Supplementary Table 3). Similar results 
were observed when cumulative incidence function 
plots were constructed for mortality and CKD 
development according to TUG (Figure 1) and OLS 
tertile groups (Supplementary Figure 3). 
 
Associations between physical performance tests and 
CKD development 
 
In a cause-specific model adjusting for sex and baseline 
eGFR, the risk of incident CKD development was 
elevated by 23% in the highest TUG tertile group 
compared with the lowest TUG tertile group (hazard 
ratio [HR], 1.23; 95% confidence interval [95% CI], 
1.10-1.38). This risk was attenuated but still statistically 
significant after adjusting for additional demographic 
and clinical variables (HR, 1.16; 95% CI, 1.03-1.30). 
Similar results were observed when the log-transformed 
TUG score was treated as a continuous variable (Table 
3). In addition, in the subdistribution hazards model 
with death as a competing risk for incident CKD, the 
relationship between TUG test scores and CKD 
development risk were similar to the main association 
of the cause-specific hazards model (Table 4). However, 
when the subjects were grouped into OLS tertiles, there 
was no association between OLS test scores and 
incident CKD. Significant relationships between OLS 
test score and CKD development risk were also not 
found in the analysis using subdistribution hazards 
model (Supplementary Table 4). Spline analysis 
revealed a linear relationship between the TUG test 
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Table 1. Baseline characteristics according to 3-m timed up and go test.  










TUG test score, s     
 Mean  9.2 ± 4.1  6.9 ± 1.2  9.6 ± 0.5 14.9 ± 6.3 
 Median (IQR)   9 (7-10)  7 (6-8)  10 (9-10)  13 (12-15) 
OLS test score, s     
 Mean  16.9 ± 10.4  17.9 ± 10.6 16.6 ± 9.5  14.7 ± 11.1 
 Median (IQR)   16 (10-20)   18 (11-21)  15 (10-20) 13 (7-20) 
Demographic data     
Male sex 15,070 (48.8)  7975 (52.6) 4698 (46.7) 2397 (42.5) 
Body mass index, kg/m2 24.2 ± 3.0 24.1 ± 2.9 24.2 ± 3.0 24.4 ± 3.1 
SBP, mmHg 130.1 ± 16.5 130.2 ± 16.6 129.8 ± 16.3 130.3 ± 16.7 
DBP, mmHg  78.8 ± 10.2  78.8 ± 10.3  78.7 ± 10.1  79.1 ± 10.2 
Smoking status     
Non-smoker 18,818 (61.0)  8893 (58.7) 6262 (62.2) 3663 (64.8) 
Ex-smoker  .5946 (19.3)  3191 (21.1) 1833 (18.2)  922 (16.3) 
Current smoker  .6107 (19.8)  3071 (20.3) 1972 (19.6) 1064 (18.9) 
Drinker 13,533 (43.8)  6947 (45.8) 4319 (42.9) 2267 (40.2) 
Comorbidities     
Diabetes mellitus  .6951 (22.5)  3240 (21.4) 2292 (22.8) 1419 (25.1) 
Hypertension 15,602 (50.5)  7636 (50.4) 5022 (49.9) 2944 (52.1) 
Arrhythmia .2067 (6.7)  997 (6.6) 696 (6.9) 374 (6.6) 
CVD  .5276 (17.1)  2394 (15.8) 1724 (17.1) 1158 (20.5) 
Myocardial infarction  .602 (2.0)  306 (2.0) 192 (1.9) 104 (1.8) 
Congestive heart failure .1934 (6.3)  891 (5.9) 614 (6.1) 429 (7.6) 
Peripheral arterial disease .1086 (3.5)  473 (3.1) 376 (3.7) 237 (4.2) 
Dementia  .460 (1.5)  213 (1.4) 149 (1.5)  98 (1.7) 
Malignancy .1937 (6.3)  953 (6.3) 629 (6.2) 358 (6.3) 
Laboratory parameters     
eGFR, mL/min/1.73 m2  84.9 ± 19.2  84.4 ± 18.6  84.9 ± 19.3  86.3 ± 20.7 
Glucose, mg/dL 101.3 ± 25.2 100.9 ± 23.9 101.5 ± 26.5 101.9 ± 26.4 
Total cholesterol, mg/dL 198.3 ± 37.8 197.2 ± 37.0 199.0 ± 38.2 199.8 ± 38.9 
HDL-C, mg/dL  53.7 ± 22.0  53.1 ± 17.6  53.8 ± 19.1  55.3 ± 33.9 
Triglyceride, mg/dL 118 [85-168] 116 [84-166] 119 [85-168] 122 [87-173] 
Note: All variables are expressed as mean and standard deviation, number and percentage, or median and 25th and 75th 
percentiles. 
Cardiovascular disease (CVD) was defined as the presence of a history of myocardial infarction, coronary artery disease, 
congestive heart failure, peripheral artery disease, or cerebrovascular disease. 
Abbreviations: TUG, 3-m timed up and go; OLS, one-leg stand; BMI, body mass index; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density 
lipoprotein cholesterol. 
 
score and incident CKD risk (Figure 2). However, no 
significant association was found between OLS test 
scores and renal outcome (Supplementary Figure 4). 
Sensitivity analyses excluding subjects with COPD, 
dementia, and CVD revealed similar findings, 
respectively (Supplementary Table 5). In addition, 
sensitivity analyses excluding those who have reached 
outcome within 2 years of physical performance test 
also showed results concordant to the findings of the 
main analysis (Supplementary Tables 6 and 7). 
Subgroup analysis 
 
To evaluate the modification effects of subgroups on the 
relationship between physical performance and incident 
CKD risk, subgroup analyses were performed in 
subgroups stratified by sex, BMI, diabetes, 
hypertension, and CVD (Supplementary Figures 5 and 
6). The association between physical performance and 
incident CKD risk was similar to that in the main 
analysis across these subgroups. 
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Table 2. Outcome event rates according to 3-m timed up and go test tertile groups. 
 Overall 
3-m timed up and go test  
Tertile 1 Tertile 2 Tertile 3 Pa 
Number of participants 30,871 15,162 10,071 5667  
Person-years 181,627 89,254 59,148 33,225  
Composite renal outcome      
 Events, n 2196 1019 722 455  
 Incidence rate per 1000 person-
years 
12.1 (11.6-12.6) 11.4 (10.7-12.1) 12.2 (11.3-13.1) 13.7 (12.5-15.0) .001 
Incident CKD      
Events, n 2142 993 711 438  
Incidence rate per 1000 person-years 11.8 (11.3-12.3) 11.1 (10.5-11.8) 12.0 (11.2-12.9) 13.2 (12.0-14.5) .002 
Incident ESRD      
 Events, n 65 28 16 21  
Incidence rate per 1000 person-years 0.36 (0.28-0.47) 0.31 (0.22-0.45) 0.27 (0.17-0.44) 0.63 (0.41-0.97) . .03 
Death      
Events, n 905 434 274 197  
Incidence rate per 1000 person-years 5.0 (4.7-5.3) .4.9 (4.4-5.3) .4.6 (4.1-5.2) .5.9 (5.2-6.8) . .01 
Note: aLog rank test. 




In this study, the association between physical 
performance and risk of incident CKD development 
was evaluated in an elderly population with normal 
renal function. This was performed by analyzing data 
from a nationwide health screening examination cohort. 
The TUG and OLS tests, which are generally utilized 
for sarcopenia evaluation, were used as surrogate 
measurements of physical performance. The incidences 
of CKD and death gradually increased with higher TUG 
test scores. In addition, higher TUG test scores were 
significantly associated with the development of CKD 
even after adjustments for multiple confounding factors. 
Moreover, the significance of this relationship was 




Figure 1. Cumulative incidence curves for mortality and chronic kidney disease development according to 3-m timed up and 
go test tertile group. Abbreviations: TUG, 3-m timed up and go test. 
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Table 3. Cause-specific hazard ratios according to 3-m timed up and go test for incident chronic kidney disease. 
 
Model 1 Model 2 Model 3 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
TUG score, per s 1.32 (1.17-1.49) <.001 1.28 (1.13-1.44) <.001 1.24 (1.09-1.40) <.001 







2 1.11 (1.01-1.22) ...04 1.11 (1.01-1.22) .03 1.11 (1.00-1.22) .04 
3 1.23 (1.10-1.38) <.001 1.17 (1.04-1.31)  .008 1.16 (1.03-1.30) .01 
Note: TUG score and high-density lipoprotein cholesterol were log-transformed due to skewed distribution. 
Model 1: adjusted for sex and estimated glomerular filtration rate. 
Model 2: adjusted for model 2 plus body mass index, systolic blood pressure, chronic obstructive pulmonary disease history, 
dementia history, diabetes mellitus history, and cardiovascular disease history. 
Model 3: adjusted for model 3 plus smoking habit, alcohol consumption, and high-density lipoprotein cholesterol. 
Abbreviations: TUG; 3-m timed up and go; HR, hazard ratio; sHR, subdistribution hazard ratio; CI, confidence interval; Ref, 
reference. 
 
Table 4. Subdistribution hazard ratios according to 3-m timed up and go test for incident chronic kidney disease with 
death as a competing event.  
 
Model 1 Model 2 Model 3 
sHR (95% CI) P sHR (95% CI) P sHR (95% CI) P 
TUG score, per s 1.30 (1.13-1.48) <.001 1.26 (1.10-1.44) <.001 1.23 (1.07-1.41)  .004 
TUG score tertile       
1 Ref  Ref  Ref  
2 1.11 (1.00-1.23) .06 1.10 (0.99-1.22) .07 1.10 (0.99-1.22) .07 
3 1.23 (1.08-1.39)  .001 1.17 (1.04-1.33) .01 1.15 (1.01-1.29) .03 
Note: TUG score and high-density lipoprotein cholesterol were log-transformed due to skewed distribution. 
aIn Fine-Gray model, mortality was considered as a competing risk. 
Model 1: adjusted for sex and estimated glomerular filtration rate. 
Model 2: adjusted for model 2 plus body mass index, systolic blood pressure, chronic obstructive pulmonary disease history, 
dementia history, diabetes mellitus history, and cardiovascular disease history. 
Model 3: adjusted for model 3 plus smoking habit, alcohol consumption, and high-density lipoprotein cholesterol. 
Abbreviations: TUG; 3-m timed up and go; HR, hazard ratio; sHR, subdistribution hazard ratio; CI, confidence interval; Ref, 
reference. 
 
hazards models. However, a significant relationship 
between OLS test score and CKD development risk was 
not found. These results suggest that poor physical 
function, evaluated using the TUG test, could be a risk 
factor for CKD development in the elderly. 
 
Previous investigations have reported significant 
associations between physical function and the risk of 
chronic disease development. Low gait speed was reported 
to be associated with increased risk of CVD in the elderly 
population as well as in dialysis-dependent CKD patients 
[23–26]. In addition, evaluation of the Women’s Health 
and Aging Study showed that physical function predicts 
catastrophic disability in activities of daily living [27]. 
Moreover, slow gait speed was reported to be a significant 
risk factor for mortality among elderly Italians [28]. In 
addition to physical performance status being a risk factor 
for chronic diseases, physical performance also predicts 
outcome in several patient groups. A recent meta-analysis 
involving 4187 cancer patients showed that physical 
performance is closely related to survival and suggested 
that physical performance tests should be used as a 
prognostic tool in patients with cancer [29]. In patients 
with Alzheimer’s disease, physical performance was found 
to be significantly related to future cognitive function [30]. 
In coronary artery disease patients, physical performance 
was reported to predict the occurrence of future 
cardiovascular events [31]. Adding to the relationships of 
physical function with poor outcome, the results of this 
study showed that poor physical function may also 
increase the probability of kidney function loss. The 
findings suggest that TUG tests could be used as a 
prognostic factor for kidney function decline in the elderly. 
 
Although a clear association between TUG test score 
and incident CKD was observed, no significant 
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relationship was found between OLS test score and 
CKD development. Several previous reports have also 
provided inconsistent findings on the association 
between OLS tests and adverse events. In a Japanese 
population of 80-year-old subjects, OLS test scores 
were not associated with overall mortality or specific 
causes of mortality such as CVD, pneumonia, and 
malignancy [32]. Investigations examining the relation 
between OLS test score and falling events also provided 
variable results. Although several studies found a clear 
difference in OLS test scores between fallers and non-
fallers, others failed to report such a difference. One of 
the reasons for this weak clinical relevance of the OLS 
test score could be related to its poor correlation with 
muscle mass. A recent investigation reported that OLS 
test scores did not show an independent correlation with 
leg muscle mass in older women [33]. In addition, the 
fact that the OLS test cannot be conducted in subjects 
with cognitive impairment or in those using a walking 
aid further limits its suitability as a performance 
measurement in elderly people. Concordantly, when 
predicting fall events among community-dwelling older 
people, the predictive value of TUG test scores 
exceeded that of OLS test scores in a recent 
investigation [34]. 
 
Although the eGFR was within the normal range in all 
TUG score groups, the TUG test scores were positively 
associated with baseline eGFR. One of the reasons for 
this relationship between TUG test score and eGFR 
could be the possibility of overestimation. TUG test 
scores are known to be related with muscle mass in the 
elderly [35]. Since serum creatinine levels are affected 
by muscle mass, eGFR is often overestimated in 
patients with lower muscle mass [36]. A similar finding 
was also observed in a recent cross-sectional study 
among older people. In that study, the TUG was lower 
in subjects with eGFR 60-89 ml/min/1.73m2 compared 
to subjects with eGFR > 90ml/min/1.73m2 which is a 
finding comparable to the results of the current 
investigation [37]. In order to allow for this relationship 
between TUG score and eGFR at baseline, the risk for 
incident CKD was adjusted for baseline eGFR in the 
multivariable hazards models. 
 
Several mechanisms may be accountable for explaining 
the association between TUG test score and CKD 
development. Gait speed, assessed using a 400-m walk 
test, was reported to be inversely associated with 
circulating inflammatory markers such as fibrinogen, C-
reactive protein, and interleukin-6 [38, 39]. As chronic 
systemic inflammation is a well-known risk factor for 
CKD development, inflammatory cytokines could be a 
factor linking physical function and CKD. This 
possibility could not be verified in this study because 
the health screening examinations conducted by the 
National Health Insurance Service (NHIS) do not 




Figure 2. Restricted cubic spline plot for incident chronic kidney disease according to 3-m timed up and go test. Note: Adjusted 
for sex, estimated glomerular filtration rate, body mass index, systolic blood pressure, chronic obstructive pulmonary disease history, 
dementia history, diabetes mellitus history, cardiovascular disease, smoking habit, alcohol consumption, and high-density lipoprotein 
cholesterol. 
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C-reactive protein. Further investigations encompassing 
data on systemic inflammation would be needed. In 
addition, metabolic derangements could have mediated 
kidney function deterioration. Several reports have 
shown a clear connection between insulin resistance and 
loss of muscle mass in the elderly [40–42]. 
Accordingly, diabetes was more prevalent among those 
with higher TUG test scores in this study. However, as 
the association between TUG test score and CKD 
remained robust even after adjusting for diabetes, 
factors other than metabolism may have played roles. 
 
This study has several strengths. First, the current study 
used a nationwide representative sample, which 
encompasses health examination results of >30,000 
individuals, enhancing the possibility that the results 
can be generalized to the general population. Second, 
the relatively long follow-up duration of 8 years is 
advantageous in detecting slowly progressing chronic 
diseases such as CKD. Finally, the cohort consisted of a 
specific age group (subjects aged 66 years). This 
minimized the confounding effect of age, which is the 
most important factor affecting physical performance 
and kidney function. The findings of this study should 
also be interpreted in light of the study limitations. First, 
limitations due to the sampled cohort study design were 
inevitable. However, the NHIS-National Sample Cohort 
was constructed using a population-based sampling 
strategy, which has been designed that the sample 
cohort truly represents the whole data set, reducing the 
possibility of any selection bias [43]. Second, 
limitations related with medical insurance claims data 
should be addressed. The cost of renal replacement 
therapy is covered by the National Health Insurance, a 
mandatory insurance for all Koreans. Therefore, the 
chances of the insurance claims data to misidentify 
ESRD outcomes would be low. The fact that the ESRD 
incidence rate (0.36 per 1000 person-year) in this study 
was somewhat higher than the annual ESRD prevalence 
reported by the Korean Society of Nephrology (KSN) 
ESRD registry data (0.25 per 1000 person), where 
registration is not mandatory, supports this notion [44]. 
However, comorbidities other than ESRD that do not 
require active health care services may not have been 
precisely identified by the claims data. In addition, the 
possibility of documentation error would also be 
inevitable in dealing with large sized administrative 
data. Moreover, influential information such as family 
history and comorbidity duration were not available due 
to the nature of the data source. Third, a confirmative 
causal link between TUG score and CKD development 
cannot be concluded owing to the retrospective design 
of the investigation. Further prospective evaluations of 
the effect of physical performance improvement on 
kidney function would be needed. Fourth, although 
biennial health examinations are the minimal 
recommendation of the NHIS for all beneficiaries, a 
potential bias exists. CKD development can be detected 
only when the subjects undergo periodic health 
examinations. Some of the subjects could have skipped 
their biannual health examinations. Finally, physical 
performance tests were conducted only once at baseline. 
Therefore, dynamic physical performance during the 
follow-up period was not taken into account.  
 
In this study, the risk of CKD development was found 
to be related to poor physical function in relatively 
healthy elderly adults. Poor TUG test scores were 
associated with both CKD development and mortality, 
whereas OLS test scores did not show significant 
relationships. These results suggest that poor physical 
performance, especially assessed through TUG test, 
could be a risk factor for kidney function decline in the 
elderly. However, further investigations clarifying the 
causal relationship between physical performance and 
incident CKD are warranted. 
 
MATERIALS AND METHODS 
 
Data source and study subjects 
 
Detailed information regarding data source are 
described in the Supplementary Methods. The present 
study was conducted in accordance with the Declaration 
of Helsinki and approved by the institutional review 
board of Yonsei University Health System Trial Center 
(approval no. 4-2018-0697). The informed consent 
requirement was waived owing to the retrospective 
nature of the analysis. Data usage was also approved by 
the national health information data request review 
committee of NHIS. According to the Act on the 
Protection of Personal Information Maintained by 
Public Institutions, the NHIS provides data on health 
examination results and detailed medical treatments 
after de-identification of individual-level data. Data 
were retrieved from the National Health Insurance 
Service-National Sample Cohort Database (NHIS-NSC 
DB), which is a retrospective population-based sample 
cohort constructed on a 2.2% representative sample of 
the Korean population. The detailed cohort profiles with 
respect to the development of the NHIS-NSC DB have 
been previously published [43]. Data acquired during 
the life transition health screening examination at age 
66 years were considered as baseline information. The 
health screening examination results obtained thereafter 
were used as follow-up data (Figure 3).  
 
Elderly adults who underwent the life transition health 
screening examination between 2007 and 2008 were 
initially screened for enrollment (N=42,132). Subjects 
who met the following criteria were excluded: (1) eGFR 
<60 mL/min/1.73 m2, presence of proteinuria in dipstick 
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urine examination at baseline visit, or history of any renal 
replacement therapy including renal transplantation and 
dialysis (2) missing data on TUG test, OLS test, follow-up 
health screening examinations, or lifestyle questionnaires 
that include information on smoking and alcohol use. A 
total of 30,871 subjects were included in the final analysis 
(Supplementary Figure 7). 
 
Data collection and measurements 
 
Baseline demographic data, including demographic and 
physical function tests and anthropometric 
measurements, were collected during the life transition 
health screening examination. Blood samples were 
obtained after ≥8-h fasting. Serum creatinine level was 
measured using an isotope dilution mass spectrometry-
calibrated method. eGFR was calculated using the 
creatinine-based CKD Epidemiology Collaboration 
equation [45]. Urine samples were collected in the 
morning after the first voiding. Urine tests were 
performed on fresh urine samples with urine reagent 
strips, using regularly calibrated semi-automatic urine 
analyzers. Urine protein amounts were determined as 
absent, trace, 1+, 2+, or 3+, which approximately 
correlate with urine protein levels of <10, 10-20, >30, 
>100, and >500 mg/dL, respectively. Proteinuria was 
considered present when the urinalysis result was higher 
than trace level. Comorbidities during the year before 
the baseline examination were defined based on 
International Classification of Diseases, Tenth Revision 
(ICD-10) codes and claim records. Hypertension was 
defined as follows: (1) systolic blood pressure >140 
mmHg or diastolic blood pressure >90 mmHg at 
baseline examination, (2) one or more ICD codes (I10-
13 or I14) with antihypertensive claim data before 
baseline examination, and (3) two or more ICD codes 
(I10-13 or I14) before baseline examination. Diabetes 
mellitus was defined as the presence of one inpatient 
E11-E14 codes (ICD-10) or >2 outpatient E11-E14 
codes in claim data or a diabetes drug code with E11-
E14 codes. The detailed operational definitions of 
comorbidities are provided in Supplementary Table 8. 
 
Exposure and outcome ascertainment 
 
TUG and OLS tests were performed by trained 
examining physicians. For the TUG test, the time taken 
to get up from a standard armchair, walk a 3-m distance, 
turn around, and return to sitting in the chair was 
recorded [46]. For the OLS test, participants had to 
stand on one leg for as long as possible with the 
contralateral leg not bearing weight. The time until 
balance was lost or until the non-weight-bearing leg 
touched the floor was recorded [47]. 
 
The primary outcome was incident CKD and the 
secondary outcome was death of any cause. Incident 
CKD was defined as at least two consecutive 
measurements of eGFR <60 mL/min/1.73 m2 during 
follow-up health examinations. Deaths and cause of 
death were ascertained from records that were linked 
with the Korean Statistical Information Service using 
unique personal identification numbers [48]. Subjects 
were censored at the date of the last health examination, 
the development of CKD, death, or the end of the study 




Detailed information regarding statistical analysis are 
described in the Supplementary Method. All analyses 
were performed using Stata version 15.1 (Stata Corp, 
College Station, TX, USA), R software 3.3.3 
(http://www.R-project.org), and SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA). The TUG and OLS test 
scores were analyzed as continuous variables, and 
tertiles of the test scores were analyzed as categorical 




Figure 3. Design of the study. Note: Data from the National Health Insurance Service-National Sample Cohort Database were used. 
Abbreviations: ICD-10, 10th revision of the International Statistical Classification of Diseases and Related Health Problems. 
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estimate the cumulative outcome curves, and the 
homogeneity of the each survival curve was evaluated 
using Gray’s test [49]. To evaluate the association 
between the physical performance tests and incident 
CKD, multistep multivariable proportional cause-specific 
hazards models were constructed. Death before reaching 
the primary outcome was considered as a competing 
outcome and censored at the time of death [50, 51]. 
Covariates hypothesized to contribute to renal function 
deterioration were included in the adjusted models. In 
model 1, sex and baseline eGFR were adjusted. Model 2 
additionally adjusted for BMI, systolic blood pressure, 
chronic obstructive pulmonary disease (COPD) history, 
dementia history, diabetes, and CVD history. Finally, 
further adjustments were made for smoking history, 
alcohol consumption, and high-density lipoprotein 
cholesterol in model 3. Subgroup analyses were 
performed according to sex, BMI, diabetes, hypertension, 
and CVD. For sensitivity analysis, the cause-specific 
models were analyzed after excluding subjects with 
comorbid diseases that can affect physical performance 
tests, including CVD, COPD, and dementia. In addition, 
the association of physical function test results and 
development of CKD in Fine-Gray models was evaluated 
[52]. The covariates that were adjusted in the cause-
specific hazards models were used in the sensitivity 
analysis. All tests were two sided. All P-values <.05 were 




TUG: 3-m timed up and go; CKD: chronic kidney 
disease; OLS: one-leg stand; NHIS-NSC DB: National 
Health Insurance Service-National Sample Cohort 
Database; eGFR: estimated glomerular filtration rate; 
ICD-10: International Classification of Diseases, Tenth 
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Data were retrieved from the National Health Insurance 
Service-National Sample Cohort Database (NHIS-NSC 
DB), which is a retrospective population-based sample 
cohort constructed on a 2.2% representative sample of 
Koreans. Korea has a single mandatory health insurance 
system, the National Health Insurance Service (NHIS), 
which maintains records of all covered medical visits, 
procedures, prescriptions, and health screening 
examinations. The detailed cohort profiles with respect 
to the development of the NHIS-NSC DB have been 
previously published [1]. 
 
The NHIS-NSC DB consists of the following data sets: 
(1) sociodemographic information and year and cause 
of death of the insurance beneficiary, which is reported 
from the Korean Statistical Information Service 
(KOSIS); (2) information on diagnosis based on 
International Classification of Diseases, Tenth Revision 
(ICD-10) codes, hospital admission, and treatment 
details including prescription of drugs and procedures; 
and (3) health screening examination data. The NHIS 
provides biannual health screening examinations that 
include laboratory tests, questionnaires for assessing 
cardiovascular risk factors, and anthropometric 
measurements (e.g., body weight, blood pressure, and 
waist circumference) to all of its beneficiaries. In 
addition to the routine biannual health screening 
examination, examinees who turn 66 years of age 
undergo a “life transition health screening 
examination”, which consists of the TUG and OLS tests 
for the evaluation of muscle function. Data acquired 
during the life transition health screening examination 
at age 66 years were considered as baseline information. 
The health screening examination results obtained 




All analyses were performed using Stata version 15.1 
(Stata Corp, College Station, TX, USA), R software 3.3.3 
(http://www.R-project.org), and SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA). Continuous variables are 
expressed as either mean ± standard deviation or median 
(interquartile range), and categorical variables are 
presented as number (percentage). To test whether the 
variables are normally distributed, the Kolmogorov-
Smirnov test was used. Analysis of variance and χ2 tests 
were used to compare the difference between categorized 
groups for continuous and categorical variables, 
respectively. The Kruskal-Wallis test was used to 
determine the difference between groups when the 
variable showed a skewed distribution. The TUG and 
OLS test scores were analyzed as continuous variables, 
and tertiles of the test scores were analyzed as categorical 
variables. Cumulative incidence function was used to 
estimate the cumulative outcome curves, and the 
homogeneity of the each survival curve was evaluated 
using Gray’s test [2]. To evaluate the association between 
the physical performance tests and incident CKD, 
multistep multivariable proportional cause-specific 
hazards models were constructed. Death before reaching 
the primary outcome was considered as a competing 
outcome and censored at the time of death [3, 4]. The 
result of cause-specific hazards models were presented as 
HRs and 95% CIs. Covariates hypothesized to contribute 
to renal function deterioration were included in the 
adjusted models. In model 1, sex and baseline eGFR 
were adjusted. Model 2 additionally adjusted for BMI, 
systolic blood pressure, chronic obstructive pulmonary 
disease (COPD) history, dementia history, diabetes, and 
CVD history. Finally, further adjustments were made for 
smoking history, alcohol consumption, and high-density 
lipoprotein cholesterol in model 3. Subgroup analyses 
were performed according to sex, BMI, diabetes, 
hypertension, and CVD. For sensitivity analysis, the 
cause-specific models were analyzed after excluding 
subjects with comorbid diseases that can affect physical 
performance tests, including CVD, COPD, and dementia. 
In addition, the association of physical function test 
results and development of CKD in Fine-Gray models 
was evaluated [5]. The covariates that were adjusted in 
the cause-specific hazards models were used in the 
sensitivity analysis. All tests were two sided. All P-
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Supplemental Figure 2. Correlation between baseline estimated glomerular filtration rate and physical performance tests for (A) 3-m 
timed up and go test and (B) One-leg stand test. Note: Pearson correlation coefficient (P-value) of 3-timed up and go test and one-leg stand 
test were 0.0321 (<.001) and 0.0092 (.71), respectively. *P<.05. 
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Supplementary Figure 3. Cumulative incidence curves for mortality and chronic kidney disease development according to 
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Supplementary Figure 4. Restricted cubic spline plot for incident chronic kidney disease according to one-leg stand test. Note: 
Adjusted for sex, estimated glomerular filtration rate, body mass index, systolic blood pressure, chronic obstructive pulmonary disease 
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Supplementary Figure 5. Subgroup analysis of the 3-m timed up and go test for incident chronic kidney disease. Note: The 3-m 
timed up and go test score was log-transformed due to skewed distribution. Adjusted for sex, estimated glomerular filtration rate, body mass 
index, systolic blood pressure, chronic obstructive pulmonary disease history, dementia history, diabetes mellitus history, cardiovascular 
disease, smoking habit, alcohol consumption, and high-density lipoprotein cholesterol. Abbreviations: CI, confidence interval; BMI, body mass 
index; DM, diabetes mellitus; HTN, hypertension, CVD; cardiovascular disease. 
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Supplementary Figure 6. Subgroup analysis of one-leg stand test for incident chronic kidney disease. Note: one-leg stand test 
score was log-transformed due to skewed distribution. Adjusted for sex, estimated glomerular filtration rate, body mass index, systolic blood 
pressure, chronic obstructive pulmonary disease history, dementia history, diabetes mellitus history, and cardiovascular disease history, 
smoking habit, alcohol consumption, and high density lipoprotein cholesterol. Abbreviations: CKD, chronic renal disease; CI, Confidence 
interval.  
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Supplementary Figure 7. Flowchart of subject selection. Abbreviations: NHIS-NSC DB, National Health Insurance Service-National 
Sample Cohort Database; TUG, 3-m timed up and go; OLS, one-leg stand. 
  
 
www.aging-us.com 17413 AGING 
Supplementary Tables 
 
Supplementary Table 1. Baseline characteristics according to one-leg stand test. 










OLS test score, s     
 Mean  16.9 ± 10.4  7.1 ± 3.4 17.6 ± 2.3  30.4 ± 11.4 
 Median (IQR)  16 (10-20)  7 (4-10) 18 (15-20)  28 (23-30) 
Demographic data     
Male sex ..15,070 (48.8) 4,170 (39.8) 6,894 (51.2) .4,006 (57.9) 
Body mass index, kg/m2 24.2 ± 3.0 24.5 ± 3.1 24.1 ± 2.9 23.9 ± 2.8 
SBP, mmHg 130.1 ± 16.5 130.8 ± 16.8 129.7 ± 16.3 129.9 ± 16.2 
DBP, mmHg  78.8 ± 10.2  79.1 ± 10.3  78.7 ± 10.1  78.8 ± 10.2 
Smoking status     
Non-smoker 18,818 (61.0) 7,046 (67.3) 7,974 (62.2) .3,798 (54.9) 
Ex-smoker  5,946 (19.3) 1,654 (15.8) 2,718 (20.2) .1,574 (22.8) 
Current smoker  6,107 (19.8) 1,776 (17.0) 2,786 (20.7) .1,545 (22.3) 
Drinker 13,533 (43.8) 4,078 (38.9) 6,120 (45.4) .3,335 (48.2) 
Comorbidities     
Diabetes mellitus  6,951 (22.5) 2,637 (25.2) 2,821 (20.9) .1,493 (21.6) 
Hypertension 15,602 (50.5) 5,545 (52.9) 6,653 (49.4) .3,404 (49.2) 
Arrhythmia 2,067 (6.7) .725 (6.9) .883 (6.6)  459 (6.6) 
CVD  5,276 (17.1) 2,046 (19.5) 2,165 (16.1) .1,065 (15.4) 
Myocardial infarction  .602 (2.0) .220 (2.1) .263 (2.0)  119 (1.7) 
Congestive heart failure 1,934 (6.3) .770 (7.4) .776 (5.8)  388 (5.6) 
Peripheral arterial disease 1,086 (3.5) .356 (3.4) .475 (3.7)  255 (3.7) 
Dementia  .460 (1.5) .174 (1.7) .190 (1.4)   96 (1.4) 
Malignancy 1,937 (6.3) .653 (6.2) .850 (6.3)  434 (6.3) 
Laboratory parameters     
eGFR, mL/min/1.73m2  84.9 ± 19.2  85.5 ± 19.9  84.1 ± 18.2  85.5 ± 20.0 
Glucose, mg/dL 101.3 ± 25.2 101.9 ± 26.2 101.2 ± 25.0 100.6 ± 24.2 
Total cholesterol, mg/dL 198.3 ± 37.8 200.1 ± 38.3 197.7 ± 37.8 199.8 ± 38.9 
HDL-C, mg/dL 52 [44-61] 52[44-61] 52 [44-60] 51 [43-61] 
Triglyceride, mg/dL 118 [85-168] 121 [87-172] 117 [83-165] 116 [84-166] 
Note: All variables are expressed as mean and standard deviation, number and percentage, or median and 25th and 75th 
percentiles 
Cardiovascular disease (CVD) was defined as the presence of a history of myocardial infarction, coronary artery disease, 
congestive heart failure, peripheral artery disease, or cerebrovascular disease. 
Abbreviations: OLS, one-leg stand; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CVD, 
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Supplementary Table 2. Cause of death according to physical performance groups. 
Cause of death, n (%) Overall Tertile 1 Tertile 2 Tertile 3 P 
Timed up and go test     .8 
Malignancy 446 (49.3) 223 (51.5) 133 (48.5)  90 (45.7)  
Cardiovascular disease 153 (16.9)  77 (17.8)  45 (16.4)  31 (15.7)  
Unintentional injury 137 (15.2)  59 (13.6)  44 (16.1)  34 (17.3)  
Respiratory disease 52 (5.8) 22 (5.1) 16 (5.8) 14 (7.1)  
Gastroenteric disease 26 (2.9) 11 (2.5)  9 (3.3)  6 (3.0)  
Endocrinologic disease 21 (2.3)  9 (2.1)  6 (2.2)  6 (3.0)  
Infective disease 13 (1.4)  5 (1.2)  7 (2.6)  1 (0.5)  
Kidney disease  4 (0.4)  3 (0.7)  0 (0.0)  1 (0.5)  
Etc 52 (5.8) 24 (5.5) 14 (5.1) 14 (7.1)  
      
One leg stand test     .2 
Malignancy 446 (49.3) 146 (42.2) 196 (55.2) 104 (51.2)  
Cardiovascular disease 153 (16.9)  62 (17.9)  58 (16.3)  33 (16.3)  
Unintentional injury 137 (15.2)  62 (17.9)  44 (12.4)  31 (15.3)  
Respiratory disease 52 (5.8) 21 (6.1) 17 (4.8) 14 (6.9)  
Gastroenteric disease 26 (2.9) 12 (3.5)  9 (2.5)  5 (2.5)  
Endocrinologic disease 21 (2.3)  9 (2.6)  8 (2.3)  4 (2.0)  
Infective disease 13 (1.4)  5 (1.4)  7 (2.0)  1 (0.5)  
Kidney disease  4 (0.4)  1 (0.3)  1 (0.3)  2 (1.0)  
Etc 52 (5.8) 28 (8.1) 15 (4.2)  9 (4.4)  
 
Supplementary Table 3. Outcome event rates according to one-leg stand test tertile groups. 
 Overall 
One leg stand test  
Tertile 1 Tertile 2 Tertile 3 Pa 
N 30,871 10,476 13,478 6,917  
Person-years 181,647 60,299 80,501 40,847  
Incident CKD      
Events, n 2,142 767 896 479  
Incidence rate per 1000 person-years 11.8 (11.3-12.3) .12.7 (11.9-13.7) 11.1 (10.4-11.9) 11.7 (10.7-12.8) .05 
Death      
Events, n 905 346 355 204  
Incidence rate per 1000 person-years .5.0 (4.7-5.3) 5.7 (5.2-6.4) 4.4 (4.0-4.9) 5.0 (4.4-5.7)  .002 
Note: aLog rank test 
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Supplementary Table 4. Hazard ratios for incident chronic kidney disease according to one-leg stand test.  
 
Model 1 Model 2 Model 3 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Cause-specific model       
OLS score, per s 0.94 (0.88-0.99) .02 0.97 (0.92-1.03) .36 0.99 (0.93-1.04) .62 







2 0.91 (0.83-1.00) .06 0.98 (0.89-1.08) .67 0.98 (0.89-1.08) .66 
3 0.89 (0.80-1.00) .05 0.96 (0.86-1.08) .52 0.97 (0.86-1.09) .59 
       
Fine-Gray modela       
OLS score, per s 0.95 (0.89-1.01) .11 0.99 (0.93-1.06) .73 0.99 (0.94-1.07) .9 
OLS score tertile       
1 Ref  Ref  Ref  
2 0.93 (0.83-1.03) .9 1.00 (0.90-1.15) .9 1.00 (0.89-1.11) .9 
3 0.91 (0.83-1.03) .9 0.98 (0.86-1.12) .9 0.99 (0.87-1.12) .9 
Note: OLS score and high-density lipoprotein cholesterol were log-transformed due to skewed distribution. 
aIn Fine-Gray model, mortality was considered as a competing risk. 
Model 1: adjusted for sex and estimated glomerular filtration rate. 
Model 2: adjusted for model 2 plus body mass index, systolic blood pressure, chronic obstructive pulmonary disease history, 
dementia history, diabetes mellitus history, and cardiovascular disease history. 
Model 3: adjusted for model 3 plus smoking habit, alcohol consumption, and high-density lipoprotein cholesterol. 




Supplementary Table 5. Cause-specific hazard ratios for incident chronic kidney disease according to physical 
performance test after excluding subjects with comorbiditiesa. 
 
Model 1 Model 2 Model 3 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
TUG score       
Time, per s 1.48 (1.26-1.73) <.001 1.46 (1.24-1.71) <.001 1.43 (1.21-1.68) <.001 
       
OLS score       
Time, per s 0.92 (0.86-0.99) .03 0.95 (0.88-1.03) .21 0.97 (0.90-1.04) .40 
Note: TUG and OLS test score, and high-density lipoprotein cholesterol were log-transformed due to skewed distribution. 
aComorbidities included chronic obstructive pulmonary disease, dementia, and cardiovascular disease. 
Model 1: adjusted for sex and estimated glomerular filtration rate. 
Model 2: adjusted for Model 2 plus body mass index, systolic blood pressure, and diabetes mellitus history. 
Model 3: adjusted for Model 3 plus smoking habit, alcohol consumption, and high-density lipoprotein cholesterol. 
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Supplementary Table 6. Hazard ratios for incident chronic kidney disease according to timed up and go test after 
excluding subjects who have reached outcome within 2 years of the physical performance test. 
 
Model 1 Model 2 Model 3 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Cause-specific model       
TUG score, per s 1.30 (1.13-1.50) <.001 1.25 (1.08-1.44)  .002 1.21 (1.05-1.40) .01 







2 1.09 (0.97-1.22) .13 1.08 (0.97-1.21) .16 1.09 (0.97-1.22) .16 
3 1.25 (1.10-1.42)  .001 1.19 (1.05-1.36)  .008 1.17 (1.03-1.34) .02 
       
Fine-Gray modela       
TUG score, per s 1.28 (1.10-1.49)  .002 1.23 (1.05-1.43)  .009 1.21 (1.03-1.41) .02 
TUG score tertile       
1 Ref  Ref  Ref  
2 1.11 (0.98-1.25) .10 1.10 (0.97-1.24) .12 1.11 (0.99-1.25) .08 
3 1.23 (1.07-1.41)  .004 1.17 (1.02-1.35) .03 1.16 (1.01-1.34) .04 
Note: TUG score and high-density lipoprotein cholesterol were log-transformed due to skewed distribution. 
aIn Fine-Gray model, mortality was considered as a competing risk. 
Model 1: adjusted for sex and estimated glomerular filtration rate. 
Model 2: adjusted for model 2 plus body mass index, systolic blood pressure, chronic obstructive pulmonary disease history, 
dementia history, diabetes mellitus history, and cardiovascular disease history. 
Model 3: adjusted for model 3 plus smoking habit, alcohol consumption, and high-density lipoprotein cholesterol. 
Abbreviations: TUG, 3-m timed up and go; HR, hazard ratio; CI, confidence interval, Ref, reference. 
 
Supplementary Table 7. Hazard ratios for incident chronic kidney disease according to one-leg stand test after 
excluding subjects who have reached outcome within 2 years of the physical performance test. 
 
Model 1 Model 2 Model 3 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Cause-specific model       
OLS score, per s 0.92 (0.86-0.98) .02 0.96 (0.90-1.03) .24 0.97 (0.90-1.03)  .31 







2 0.90 (0.81-1.01) .08 0.96 (0.86-1.07) .45 0.96 (0.86-1.08)  .51 
3 0.86 (0.75-0.99) .03 0.92 (0.80-1.05) .24 0.93 (0.81-1.07)  .30 
       
Fine-Gray modela       
OLS score, per s 0.94 (0.87-1.01) .08 0.98 (0.90-1.05) .55 0.98 (0.91-1.06) .9 
OLS score tertile       
1 Ref  Ref  Ref  
2 0.92 (0.82-1.04) .20 0.98 (0.87-1.10) .72 0.99 (0.87-1.11) .8 
3 0.87 (0.75-1.01) .07 0.93 (0.80-1.08) .35 0.94 (0.81-1.09)  .44 
Note: OLS score and high-density lipoprotein cholesterol were log-transformed due to skewed distribution. 
aIn Fine-Gray model, mortality was considered as a competing risk. 
Model 1: adjusted for sex and estimated glomerular filtration rate. 
Model 2: adjusted for model 2 plus body mass index, systolic blood pressure, chronic obstructive pulmonary disease history, 
dementia history, diabetes mellitus history, and cardiovascular disease history. 
Model 3: adjusted for model 3 plus smoking habit, alcohol consumption, and high-density lipoprotein cholesterol. 
Abbreviations: OLS, one-leg stand; HR, hazard ratio; CI, confidence interval, Ref, reference. 
  
 
www.aging-us.com 17417 AGING 
Supplementary Table 8. ICD-10 codes used for comorbidity detection. 
Comorbidities Definitions ICD-10 Codes or Procedure codes 
Myocardial infarction Defined from diagnosis* ICD-10: I21, I22, I25.2 
Hypertension Composite of following: 
>140/90 mmHg at baseline 
examination 
one or more ICD codes (I10-13 or 
I14) with antihypertensive 
two or more ICD codes prior to 
baseline examination 
ICD-10: I10, I11, I12, I13, I15 plus all 
kinds of oral antihypertensive 
Diabetes mellitus Defined from diagnosis* plus 
treatment 
ICD-10: E10, E11, E12, E13, E14 
Treatment: all kinds of oral antidiabetics 
and insulin 
Peripheral arterial disease Defined from diagnosis* ICD-10: I70, I71 
Congestive heart failure Defined from diagnosis* ICD-10: I11.0, I50, I97.1 
Malignancy Defined from diagnosis* ICD-10: C00-C97 
Chronic obstructive pulmonary 
disease 
Defined from diagnosis* plus 
treatment 
ICD-10: J42, J43(except J43.0), J44 
Treatment: SABA, SAMA, LABA, 
LAMA, ICS, ICS+LABA, or 
methylxanthine (>1 months). 
Dementia Defined from diagnosis* ICD-10: F00, F03, G30, G31 
History of renal replacement 
therapy 
Defined from hemodialysis or 
peritoneal dialysis, claim code or 
operation of kidney transplantation 
Korean procedure codes: O7010, O7020, 
O7061, O7062, O9991 
Note: * To ensure accuracy, comorbidities were established based on one inpatient or two outpatient records of ICD-10 
codes in the database 
Abbreviations: ICD-10, 10th revision of the International Statistical Classification of Diseases and Related Health Problems; 
SABA, Short acting beta agonists; SAMA, short acting muscarinic antagonist; LAMA, long acting muscarinic antagonist; LABA, 
long acting beta agonists; ICS, Inhaled corticosteroids. 
 
